BlueSkeye AI.

ethical ai for metal health analysis.

Blueskeye AI Ltd is deploying novel methods of analysing medically relevant human behaviour from video streams to improve wellbeing and assist in diagnosis, treatment and monitoring of mental health conditions. The company spun out from the University of Nottingham in 2019.

Technology & Products.

The company’s proprietary technology utilises artificial intelligence techniques to extract information from video on a subject’s emotional state.  Machine learning is utilised to continually improve accuracy.    A priority patent application was filed in 2019.  Initial proof of concept data has been obtained from human volunteers demonstrating detection of anxiety, depression, pain, autism and ADHD.  The company has initiated 2 small-scale clinical trials in mental health indications.

The Market.

1 in 4 people will be diagnosed with a mental health problem during their lifetime. However, assessing sufferers remains highly subjective and still relies heavily on the opinion of trained medical professionals.  There is a huge opportunity for tools to provide objective assessment to improve patient care and allow people to monitor their own wellbeing.  For example, 6m people in the UK suffer from depression with an estimated economic cost of £8bn per annum.  The market for personal wellbeing continues to grow with the UK healthcare apps market expect to grow to £460m in 2020.

Business Model.

The company will develop software for wellbeing and medical applications and look to commercialise these through healthcare providers, insurance companies, retailers, pharmaceutical companies and clinical trial organisations. In the meantime, the company is undertaking paid development contracts for third parties to provide an initial funding stream.

Fundraising to date.

The company has raised £100k in the form of a convertible loan from the University of Nottingham.  A fundraising round of £650k is currently underway.

Team.

Chairman: The company is currently seeking an Executive Chairman

Interim CEO: Dr Antony Brown. Company co-founder who has led the spin out from the University of Nottingham.  With 18 years of experience as a software developer, he is a key member in development of Blueskeye AI’s technology platform.

CSO: Dr Michel Valstar. Company co-founder and world-leading expert in automatic analysis of facial expressions.  Lead inventor of the Blueskeye’s technology platform and Associate Professor in Computer Science at the University of Nottingham. Michel continues to direct development of Blueskeye’s ground-breaking technology.

Contact: Andrew Naylor, CEO, Nottingham Technology Ventures.  andrew.naylor@nottingham.ac.uk 

KEY FEATURES.

9C12A659-F601-4D82-B0B7-58B26B8FB50E

Office space

In oculis quidem se esse vult, summumque malum et, quantum.

Lab space

In oculis quidem se esse vult, summumque malum et, quantum.

Business support

In oculis quidem se esse vult, summumque malum et, quantum.

8BA7CC87-ADB9-4E9E-B6B0-0F609EA2D3A9

Meeting rooms

In oculis quidem se esse vult, summumque malum et, quantum.

Virtual tenancy

In oculis quidem se esse vult, summumque malum et, quantum.

Hot desks

In oculis quidem se esse vult, summumque malum et, quantum.

IP Status

In oculis quidem se esse vult, summumque malum et, quantum.

Opportunity

In oculis quidem se esse vult, summumque malum et, quantum.

Application areas

In oculis quidem se esse vult, summumque malum et, quantum.

Management Team

In oculis quidem se esse vult, summumque malum et, quantum.

27D4EAE4-6FBF-4578-BCBD-4F102E515086

Investment Stage

In oculis quidem se esse vult, summumque malum et, quantum.

1EEFF807-B5A2-4190-89BC-DE59BFF00B15

Investors

In oculis quidem se esse vult, summumque malum et, quantum.

Technology Readiness

In oculis quidem se esse vult, summumque malum et, quantum.

Make An Enquiry.